SQM Swears Lithium Prices Must Rise — Just Don't Ask When
Demand growth is the story management wants told, potash is the story it's quietly retiring, and the sodium-ion question is now a three-quarter ritual.
SQM · Earnings Call · 2026-11-18
A price call with no date on it
SQM's third-quarter 2026 call opened with the number that defines the whole narrative: close to $1.6 billion of net income in the first nine months, almost 4x the same period last year. Then CEO Ricardo Ramos spent most of his three minutes on a lithium market that has fallen sharply from its mid-year peak and on his conviction that this is temporary. “Although lithium market today -- price today is significantly lower since the peak observed during the second quarter, we continue to see healthy demand growth for lithium. Consequently, it's reasonable to expect prices should increase in the near future.” — Ricardo Ramos, CEO · 2026-11-18 The keyword Demand growth tops the company's curated themes this quarter with the highest momentum of any SQM keyword in two years — a tell that the entire call is being engineered around a demand argument rather than a price argument.
That framing is doing a lot of work. Analyst Joel Jackson opened Q&A with the honest version of the problem — "a lot of concerns about 2027" — and asked how much of the 30% 2026 demand growth was end-use consumption versus inventory building. By the fourth analyst, Isabella Simonato of Bank of America, the question had become more pointed: if prices keep sliding, when does the inflection come? The answer was circular. “We don't know when the prices will increase, but we do expect, of course, a price increase in the near future.” — Pablo Hernandez, Executive, Lithium Business · 2026-11-18 "Near future" is the load-bearing phrase of the quarter.
The one answer that genuinely changed
Here is where the current call diverges from the last one, and it is the most interesting detail on the transcript. In August 2026, Ben Isaacson of Scotiabank pressed exactly the same inventory question and got a candid admission: “we have seen much larger shipments of batteries for BESS than actual deployments of those batteries.” — Pablo Hernandez, Executive (market analyst or strategy) · 2026-08-19 Pablo Hernandez went further, flagging a pull-forward of sales from 2027 tied to removed Chinese export rebates, and warning of a possible slowdown in the pace of BESS implementation.
Three months later the same executive was asked about inventory again and said the opposite: “out of the 30%, we believe most of that has been end customers, as we have seen and you have seen in the market, the inventory levels have dropped during this year.” — Pablo Hernandez, Executive, Lithium Business · 2026-11-18 That is a clean about-face on the single metric that determines whether 2027 demand is real or borrowed. Either the channel genuinely destocked between August and November, or the August caution was walked back because it was uncomfortable. The call gives no data to settle it — only a directional claim and a 15% to 20% 2027 growth number derived from it.
And finally, I would say it's important to also remember that the current price level seems to be sitting below the necessary incentive price required to bring new supply to fulfill this demand. And therefore, we should expect some price increase in the future.
The incentive-price argument is SQM's structural bull case and it has been repeated verbatim for several quarters. What's new is the company's willingness to hang 2027 guidance on it while the spot price moves the other way. Note also what is absent from the global tape: lithium does not appear anywhere in the market's top advancers or decliners across 360-, 90- or 30-day windows. This is not a market-wide trade being repriced. It is a single-name conviction play.
Potash retires quietly; sodium-ion refuses to die
Buried in the Q&A is a genuine structural shift. Potash has been a byproduct for SQM at Novandino for years, and management has hinted at shrinkage before. On this call the language hardened: Corinne Blanchard of Deutsche Bank asked for 2027 potassium chloride volumes, and got “the volumes are going to go down. We don't know yet at what level, but you can consider that what we have been selling this year is going to be higher than next year.” — Juan Bellolio, Executive, Agriculture Business · 2026-11-18 The new keyword availability of potash captures this precisely — potash is now discussed as a question of what's left over after lithium, not a business line to grow. Contrast that with August 2025, when management described the plant nutrition franchise in expansive terms of adding products and services. The franchise has been narrowed to potassium nitrate and whatever potash happens to be spare.
Meanwhile the sodium ion question has become a ritual. It was asked in March 2026 ("we see a small potential market space for the sodium-ion batteries"), asked again in August 2026, and asked again on this call by Jackson, with Hernandez delivering a near-identical answer about lithium's cost and energy-density advantages. Three consecutive quarters, three identical answers, zero change in the disclosure. That is a signal about persistent investor anxiety rather than about sodium-ion itself.
The plant nutrition business is where the honesty surfaced fastest. Volumes disappointed because phosphates got expensive, and full-year growth guidance was cut to roughly 5%. “We sold a huge volume in Q2. So if you consider the balance between Q2 and Q3, it's more or less the same volume than last year... Q3 could be something exceptional.” — Juan Bellolio, Executive, Agriculture Business · 2026-11-18 The keyword high prices — which for other companies means pricing power — here means demand destruction in SQM's own distribution channel.
Spending a billion a year into a falling price
Perhaps the most quietly contrarian fact on the call: CapEx guidance is untouched. Bradesco's Matheus Moreira noted disbursements below $500 million year-to-date and asked whether SQM was throttling spending. CFO Gerardo Illanes said no — the three-year program is still around $3 billion, roughly $1 billion a year. Ramos was blunter when Ben Isaacson asked whether the spending cadence changes at current prices: “We remain the same. We don't foresee any reason to change our capital expenditure considering what is today price environment.” — Ricardo Ramos, CEO · 2026-11-18 A producer with the industry's lowest cost position can afford that; a producer without it cannot. That asymmetry is the actual bull case, and it's better than the price forecast.
The offsetting evidence is on the operational side. Cost performance at Novandino held roughly flat quarter-over-quarter and is expected to stay there into 2027 despite inflation and energy costs, with production guided to about 290,000 tonnes this year and just over 300,000 next. At Mount Holland the concentrator is running at or above nameplate, with 175,000 to 185,000 tonnes of 6% spodumene concentrate guided, and the direct sales mix still undecided pending refinery ramp. Iodine delivered its usual steady refrain — over 3% demand growth in 2026 and 2027, demand for iodine anchored by contrast media — and it is the one segment where nothing appears to be under stress.
The trade, distilled
SQM is asking investors to underwrite a cost-curve argument and a demand argument while explicitly declining to date the price inflection, while reversing its own inventory commentary from 90 days ago, while quietly retiring potash, and while answering the sodium-ion question for the third straight quarter with the same paragraph. The $1.6 billion of nine-month net income is real. So is the leverage to a price that management admits it cannot forecast. What the call does not provide is any new evidence that 2027 demand isn't partially borrowed from a battery-storage channel that management itself flagged as over-shipped in August. Until that line is reconciled, this is a well-run, low-cost producer waiting on a market that hasn't yet agreed with it.